HomeNASDAQ:AMGN

NASDAQ:AMGN

Amgen Skyrockets as CEO Touts MariTide Obesity Drug Progress

Amgen Skyrockets as CEO Touts MariTide Obesity Drug Progress

May 3, 2024

Should You Buy Amgen Stock for Its 3% Yield?

Should You Buy Amgen Stock for Its 3% Yield?

April 29, 2024

FTC Approves Amgen’s $28 Billion Horizon Buyout

FTC Approves Amgen’s $28 Billion Horizon Buyout

September 4, 2023

Amgen Posts 6% Increase in Quarterly Revenue, Exceeds Profit Expectations

Amgen Posts 6% Increase in Quarterly Revenue, Exceeds Profit Expectations

August 4, 2023

Amgen Stock Prices Continue To Fall Following Their All-cash Acquisition of Horizon

Amgen Stock Prices Continue To Fall Following Their All-cash Acquisition of Horizon

December 14, 2022

Amgen’s Year-to-Date Performance Exceeds Expectations; Now What?

Amgen’s Year-to-Date Performance Exceeds Expectations; Now What?

August 30, 2022

Amgen Reduces Its Sales Forecast After Announcing Plans To Acquire ChemoCentryx

Amgen Reduces Its Sales Forecast After Announcing Plans To Acquire ChemoCentryx

August 5, 2022